|1.||Ranieri, Girolamo: 4 articles (10/2015 - 01/2013)|
|2.||Andriulli, Angelo: 4 articles (04/2007 - 10/2002)|
|3.||Ammendola, Michele: 3 articles (10/2015 - 01/2013)|
|4.||Sacco, Rosario: 3 articles (10/2015 - 01/2013)|
|5.||Sammarco, Giuseppe: 3 articles (10/2015 - 01/2013)|
|6.||Leandro, Gioacchino: 3 articles (04/2007 - 10/2002)|
|7.||Pezzilli, Raffaele: 3 articles (01/2006 - 05/2003)|
|8.||Mariani, Alberto: 3 articles (10/2003 - 04/2002)|
|9.||Marech, Ilaria: 2 articles (10/2015 - 01/2014)|
|10.||De Sarro, Giovambattista: 2 articles (10/2015 - 01/2014)|
03/01/2003 - "Gabexate mesilate has been proven effective in the treatment of severe acute pancreatitis with organ dysfunction. "
07/01/2000 - "There are strong indications from this study that early intravenous gabexate mesilate infusion results in improved survival in acute pancreatitis with organ dysfunctions."
01/01/2007 - "Long-term (12 hours) infusion of gabexate significantly decreased the incidence of post-ERCP pancreatitis; however, no prophylactic effect was observed for short-term infusion (2.5 and 6.5 hours). "
08/01/2006 - "Routine gabexate prophylaxis was associated with a significant reduction of post-ERCP pancreatitis rate, severe hyperamylasaemia and hospitalisation-related costs only in high-risk patients. "
06/01/2006 - "The administration of gabexate mesilate has been reported to be effective for the prevention for post-ERCP pancreatitis when given during and after the procedure. "
09/01/2003 - "Continuous infusion of gabexate mesilate proved effective for improvement of systemic bleeding tendency. "
05/01/1986 - "FOY is an effective agent and may decrease postdialysis bleeding complications in certain high-risk patients."
08/01/2006 - "Beneficial effect of gabexate mesilate on microscopic polyangiitis with renal dysfunction and pulmonary hemorrhage: A case report."
11/01/2000 - "The combined use of heparin and gabexate mesilate was considered to be very effective for improving this condition, although a slight increase in rectal bleeding was recognized for a short time."
06/01/1988 - "Although the therapeutic efficacy of gabexate was not significantly different from that of heparin, in patients in whom bleeding tendencies were observed at the start of the therapy, the former was successful in four (80%) of five patients, while the latter was effective in only one (25%) of four patients treated. "
|3.||Disseminated Intravascular Coagulation
09/01/2012 - "Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study."
11/01/1993 - "Treatment of disseminated intravascular coagulation with gabexate mesilate."
06/01/1988 - "Gabexate as a therapy for disseminated intravascular coagulation."
01/01/1983 - "Protective effect of gabexate mesilate against experimental disseminated intravascular coagulation in rats."
05/01/1982 - "[Protection of endotoxin-induced disseminated intravascular coagulation in rats by gabexate mesilate]."
09/01/2004 - "Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery."
04/01/1990 - "On the basis of this study the hypothesis is not confirmed that treatment with gabexate mesilate for necrotizing experimental pancreatitis with additional gram-negative infection has a therapeutic efficiency."
09/01/2012 - "Antithrombin may be a more effective treatment for coagulation and fibrinolysis disorders than gabexate mesilate in infection-related DIC, but there was no difference in 28-day mortality."
09/01/1994 - "This characteristic of gabexate mesilate may facilitate protection against infecting micro-organisms, although the inhibition of reactive oxygen species production by neutrophils may be a disadvantage for host-defense against infection."
09/01/2012 - "Sixteen adult patients with a diagnosis of DIC with infection who were assessed with an acute DIC score 4 or higher at the admission to the intensive care unit were divided into antithrombin-treated and gabexate mesilate-treated groups. "
12/01/1996 - "For this drug numerous mechanisms of action have been postulated; protease inhibition, direct or indirect lysosomal membrane stabilization, etc. The aim of this study has been to verify if Foy would express antioxidant properties against free radical overgeneration, responsible for the increase in microvascular permeability which represents one of the most important pathogenetic phenomenon of any condition of shock. "
05/01/1993 - "Evaluation of seriousness of shock on beginning of therapy and during the follow-up period was performed on the basis of the same "shock score" (Ogawa and Fujita, Jap J Surg 12:122, 1982) that was used in Japanese clinical studies on FOY in shock. "
05/01/1990 - "In 1987, Foy et al. reported that hippocampal LTP was impaired by exposure to inescapable shock. "
09/01/2000 - "She recovered promptly with PCG, gabexate mesilate and intensive care for shock. "
01/01/2002 - "It rarely induces anaphylaxis, and patients with gabexate mesilate-induced shock had been reported to survive with appropriate treatments including respiratory support. "
|2.||Protease Inhibitors (Protease Inhibitor)
|3.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|8.||FOY 305 (camostat)
|9.||Serine Proteases (Serine Protease)
|10.||Peptide Hydrolases (Proteases)
|3.||Renal Dialysis (Hemodialysis)
|4.||Transplantation (Transplant Recipients)
|5.||Drug Therapy (Chemotherapy)